| http://www.w3.org/ns/prov#value | - All eight pre-specified secondary endpoints in the ASTERIA II trial were met for the 150 mg and 300 mg doses, except for the 150 mg dose that did not show a significant difference from placebo in the proportion of angioedema-free days from Week 4 to Week 12 of therapy.CIU is a distressing skin condition characterized by red, swollen, itchy and sometimes painful hives on the skin, spontaneously pre
|
